Medical Oncology

, Volume 25, Issue 4, pp 467–470 | Cite as

Chronic myeloid leukemia following the treatment of rectal adenocarcinoma

  • Gurhan Kadikoylu
  • Irfan Yavasoglu
  • Sabri Barutca
  • Nezih Meydan
  • Zahit Bolaman
Case Report


Solid tumors may occur in 3% of the patients with chronic myeloid leukemia (CML). Philadelphia (Ph)-positive CML was diagnosed in a 66-year-old man upon a white blood cell count of 58.1 × 109/L. He had no symptoms and physical findings 3 years after treatment for rectal adenocarcinoma. Imatinib mesylate 400 mg/day was started and white blood cell count was lowered to 5.7 × 109/L in 1 month. The patient had received several chemotherapeutic agents such as 5-fluorouracil, irinotecan, raltitrexed, capecitabine, and oxaliplatin. In the literature, there are two reports on CML after the treatment of colorectal carcinoma. The possibility of a relationship between oxaliplatin and/or irinotecan and CML may not be fully excluded. In conclusion, hematological disorders such as CML may emerge in colorectal carcinoma and whole blood counts should be carefully checked. The possibility of a relationship between CML and the chemotherapeutic agents in colorectal carcinoma should be further evaluated.


Chemotherapy Chronic myelogenous leukemia Rectal adenocarcinoma 


  1. 1.
    Lichtman MA, Liesveld JL. Chronic myelogenous leukemia and related disorders. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, editors. Williams hematology. United States of America (International Edition): McGraw Hill; 2006. pp. 1237–94.Google Scholar
  2. 2.
    Alfiar F, Amato D, Lipton JH. Chronic myeloid leukemia in a woman with papillary carcinoma of the thyroid treated with radioactive iodine. Leuk Lymphoma. 1997;27:365–7.PubMedGoogle Scholar
  3. 3.
    Pamuk GE, Turgut B, Vural O, et al. Metastatic squamous cell carcinoma of the skin in chronic myeloid leukaemia: complication of hydroxyurea therapy. Clin Lab Haematol. 2003;25:329–31.PubMedCrossRefGoogle Scholar
  4. 4.
    Waller CF, Fetscher S, Lange W. Secondary chronic myelogenous leukemia after chemotherapy followed by adjuvant radiotherapy for small cell lung cancer. Leuk Res. 1999;23:961–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Porta C, Casagranda I, Semino G, et al. Chronic myeloid leukemia following cyclophosphamide-containing chemotherapy in a breast cancer patient. Haematologica 1993;78:56–7.PubMedGoogle Scholar
  6. 6.
    Gola A, Reszko A. Chronic granulocytic leukemia and an organ neoplasm in the same person (Abstract). Pol Tyg Lek. 1996;51:289–90.PubMedGoogle Scholar
  7. 7.
    Buxhofer-Ausch V, Hinterberger-Fischer M, Hinterberger W. Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan. Eur J Haematol. 2006;76:447–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Gokel Y, Paydas S. Chronic myeloid leukemia in a patient with colon adenocarcinoma. Haematologica (Bud). 2002;32:501–3.Google Scholar
  9. 9.
    Slade R, Thomas WE. Gastrointestinal malignancies as a complication of chronic myeloid leukaemia. Br J Clin Pract. 1990;44:76–8.PubMedGoogle Scholar
  10. 10.
    Nakamura H, Inokuchi K, Hanawa H, et al. A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma. Ann Hematol. 2000;79:396–401.PubMedCrossRefGoogle Scholar
  11. 11.
    Katoh M, Takeuchi K, Murashima N, et al. Hepatocellular carcinoma with splenic metastasis developing after 16 years of chemotherapy for chronic myelogenous leukemia: a case report. Jpn J Clin Oncol. 1994;24:111–5.PubMedGoogle Scholar
  12. 12.
    Waller CF, Fetscher S, Lange W. Treatment-related chronic myelogenous leukemia. Ann Hematol. 1999;78:341–54.PubMedCrossRefGoogle Scholar
  13. 13.
    Aguiar RC. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma. 1998;29:17–26.PubMedCrossRefGoogle Scholar
  14. 14.
    Dann EJ, Rowe JM. Biology and therapy of secondary leukaemias. Best Pract Res Clin Haematol. 2001;14:119–37.PubMedCrossRefGoogle Scholar
  15. 15.
    Pedersen-Bjergaard J, Brondum-Nielsen K, Karle H, et al. Chemotherapy-related-late occurring—Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors? Leukemia. 1997;11:1571–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Nandakumar A, Davis S, Moolgavkar S, et al. Myeloid leukaemia following therapy for a first primary cancer. Br J Cancer. 1991;63:782–8.PubMedGoogle Scholar
  17. 17.
    Greene MH. Is cisplatin a human carcinogen? J Natl Cancer Inst. 1992;84:306–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999;340:351–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Hartmann JT, Lipp HP. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II-mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf. 2006;29:209–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Nishio S, Sugiyama T, Shouji T, et al. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer. Gynecol Oncol 2007;106:342–7.Google Scholar
  21. 21.
    Patel S, Liu D, Caron P, et al. Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine. Leuk Lymphoma. 2007;48:1032–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Merlin F, Prochilo T, Kildani B, et al. Secondary acute lymphoblastic leukaemia following oxaliplatin for adjuvant chemotherapy in colon cancer. Acta Oncol 2007;1–2; Epub 2007 Sep 12.Google Scholar
  23. 23.
    Carneiro B, Kaminer L, Eldibany M, et al. Oxaliplatin-related acute myelogenous leukemia. Oncologist. 2006;11:261–2.PubMedCrossRefGoogle Scholar
  24. 24.
    Merrouche Y, Mugnert F, Cahn JY. Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer. Acta Oncol. 2006;17:1025–6.Google Scholar

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  • Gurhan Kadikoylu
    • 1
  • Irfan Yavasoglu
    • 1
  • Sabri Barutca
    • 2
  • Nezih Meydan
    • 2
  • Zahit Bolaman
    • 1
  1. 1.Division of HematologyAdnan Menderes University Medical FacultyAydinTurkey
  2. 2.Division of OncologyAdnan Menderes University Medical FacultyAydinTurkey

Personalised recommendations